AstraZeneca Acquisition News – AstraZeneca Acquires Amolyt Pharma
Jul 15, 2024 | By Team SR
![AstraZeneca announced the successful completion of the acquisition of Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases.](https://startuprise.co.uk/wp-content/uploads/2024/07/AstraZeneca-1.webp)
AstraZeneca announced the successful completion of the acquisition of Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases.
SUMMARY
- AstraZeneca announced the successful completion of the acquisition of Amolyt Pharma
- Amolyt Pharma is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases.
The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline and expands on its bone metabolism franchise with the notable addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism.
Read also - Grand Games funding news – Grand Games Raises $3m Funding Led by Earlybird Digital East Fund
RECOMMENDED FOR YOU
![recomd](https://startuprise.co.uk/wp-content/uploads/2024/06/Barcelona-based-TravelPerk-Acquired-AmTrav.webp)
TravelPerk acquisition news – Barcelona-based TravelPerk Acquired AmTrav
Startup Rise EU
Jun 18, 2024
In patients with hypoparathyroidism, a deficiency in parathyroid hormone (PTH) production results in significant dysregulation of calcium and phosphate, which can lead to life-altering symptoms and complications, including chronic kidney disease.1 This programme, together with Amolyt’s talent, expertise and earlier pipeline, will enable Alexion’s expansion into rare endocrinology.
Under the terms of the definitive agreement, AstraZeneca has acquired all of Amolyt Pharma’s outstanding shares for a total consideration of up to $1.05 billion, on a cash and debt free basis. This includes $800 million upfront at deal closing, plus the right for Amolyt Pharma’s shareholders to receive an additional contingent payment of $250 million payable upon achievement of a specified regulatory milestone. AstraZeneca looks forward to welcoming the employees of Amolyt Pharma.
Notes
Neither AstraZeneca nor Amolyt Pharma undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in AstraZeneca’s Annual Report on Form 20-F for the year ended 31 December 2023, as amended by any subsequent filings made with the SEC.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.
About Amolyt Pharma
Amolyt Pharma is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors.